Latest Articles

  • Company Logo for PFE

    Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?

    Pfizer (NYSE: PFE) reported its Q4 results last month, with revenues missing but earnings beating the street estimates. The company reported revenue of $14.2 billion and an adjusted profit of $0.10 per share compared to the consensus estimates ...


  • Company Logo for PFE

    Should You Pick Pfizer Stock At $30?

    Pfizer (NYSE: PFE) reported its Q3 results earlier this week, with revenues missing but earnings beating the street estimates, and we believe that PFE stock has ample room for growth, as discussed below. The company reported revenue of $13.2 bi...



  • Company Logo for PFE

    Will Pfizer Stock See Higher Levels Post Q1 Earnings?

    Pfizer (NYSE: PFE) is scheduled to report its Q1 2023 results on Tuesday, May 2, and we expect it to see higher levels, with its revenue and earnings expected to exceed the consensus estimates. Its Covid-19 vaccine and the antiviral pill will see...


  • Company Logo for PFE

    Is Pfizer Stock Undervalued At $40?

    Pfizer stock (NYSE: PFE) has seen a fall of 21% this year, compared with 2% returns for the broader S&P500 index. Pfizer stock has been weighed down due to an anticipated decline of over 30% in its 2023 sales, primarily due to lower sales o...


  • Company Logo for PFE

    This Logistics Company Appears To Be A Better Pick Over Pfizer Stock

    We believe that FedEx stock  (NYSE: FDX) is a better pick than the pharmaceutical giant Pfizer stock   (NYSE: PFE), given its better prospects. Although these companies are from different sectors, we compare them because they have a similar re...


  • Company Logo for PFE

    What To Expect From Pfizer’s Q4?

    Pfizer (NYSE: PFE) is scheduled to report its Q4 2022 results on Tuesday, January 31, and we expect it to see little movement, with its revenue falling slightly ahead, but earnings likely missing the consensus estimates. Its Covid-19 vaccine and ...


  • Company Logo for PFE

    Is Pfizer Stock A Better Pick Over This Pharmaceuticals Bellwether?

    We believe that  Pfizer stock   (NYSE: PFE) is currently a better pick than its peer, Johnson & Johnson stock   (NYSE: JNJ), given its relatively lower valuation of 3.1x trailing revenues, compared to 4.9x for J&J. We think that this val...


  • Company Logo for PFE

    Company Of The Day: Pfizer

    What? Pfizer (NYSE:PFE) posted a stronger-than-expected set of Q3 2022 results. Although revenue declined by about 6% versus last year to $22.6 billion, it came in ahead of estimates. Adjusted earnings stood at $1.78 per share, up 40% versus la...


  • Company Logo for PFE

    Should You Buy Pfizer Stock Ahead of Its Q3 Results?

    Pfizer (NYSE: PFE) is scheduled to report its Q3 2022 results on Tuesday, November 1, and we expect it to post revenue and earnings above the consensus estimates. Its Covid-19 vaccine and the antiviral pill will continue to aid revenue growth. Ho...


  • Company Logo for PFE

    Pfizer’s Peer Appears To Be A Better Pharmaceuticals Pick

    We believe that  Merck stock   (NYSE: MRK) is currently a better pick than its peer, Pfizer stock   (NYSE: PFE), despite its higher valuation of 3.8x trailing revenues vs. 2.5x for Pfizer. This valuation gap can be attributed to Merck’s su...


  • Company Logo for PFE

    Should You Buy Pfizer Stock After An Upbeat Q2?

    Pfizer stock   (NYSE: PFE) reported its Q2 results last week, with revenue and earnings comfortably above ours and the street estimates. However, PFE stock has seen a fall of around 5% in a week as the company didn’t raise its full-year ou...


  • Company Logo for PFE

    Should You Buy Pfizer Stock Ahead of Its Q2 Results?

    Pfizer (NYSE: PFE) is scheduled to report its Q2 2022 results on Thursday, July 28, and we expect it to post revenue and earnings well above the consensus estimates. Its Covid-19 vaccine and the antiviral pill will continue to drive revenue growt...


  • Company Logo for PFE

    Should You Buy, Sell, Or Hold Pfizer Stock At $52?

    After an 8% fall year-to-date, at the current levels, we believe Pfizer stock (NYSE: PFE) has some room for growth. PFE stock fell from $57 in early January to $52 now. The YTD -8% return for PFE marks an outperformance with -19% returns for th...


  • Company Logo for FDX

    Here’s A Better Pick Over FedEx Stock

    We think that  Pfizer stock (NYSE: PFE) currently is a better pick compared to FedEx stock   (NYSE: FDX), despite it being the more expensive of the two, trading at 3.3x trailing revenues compared to 0.6x for FedEx. The gap in the valuation of ...

Next ▶